TITLE

Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI

AUTHOR(S)
Yuiuf, Salim
PUB. DATE
September 2005
SOURCE
ACP Journal Club;Sep/Oct2005, Vol. 143 Issue 2, p43
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study by researcher K. Malmberg and colleagues, which found that intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI. The study found that in patients with type 2 diabetes and acute myocardial infarction, an insulin-glucose regimen with long-term insulin control was not better than an insulin regimen with standard glucose control for improving survival. In patients with diabetes, no strong evidence exists that lowering glucose prevents macrovascular disease, although it can clearly prevent microvascular disease.
ACCESSION #
18427114

 

Related Articles

  • How metformin controls blood glucose. Morris, David // GP: General Practitioner;3/25/2002, p56 

    Focuses on the efficacy of metformin in regulating glucose in the circulation. Administration of metformin in type-2 diabetic patients; Reduction of myocardial infarction; Mechanism of action.

  • A Functional Tyr1306Cys Variant in LARG Is Associated With Increased Insulin Action in Vivo. Kovacs, Peter; Stumvoll, Michael; Bogardus, Clifton; Hanson, Robert L.; Baier, Leslie J. // Diabetes;May2006, Vol. 55 Issue 5, p1497 

    Diminished insulin sensitivity is a characteristic feature of type 2 diabetes. Inhibition of insulin action, resulting in reduced skeletal muscle glucose uptake, is mediated in part through stimulation of RhoA activity. One regulator of RhoA activity is leukemia-associated Rho guanine nucleotide...

  • oral hypoglycaemic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p413 

    The article presents information on oral hypoglycaemic drugs which are usually synthetic agents taken by mouth to reduce the levels of glucose (sugar) in the bloodstream and are used mainly in the treatment of Type II diabetes (non-insulin-dependent diabetes mellitus; maturity-onset diabetes)...

  • log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males. Hermans, Michel P.; Ahn, Sylvie A.; Rousseau, Michel F. // Cardiovascular Diabetology;2010, Vol. 9, p88 

    Background: T2DM is associated with atherogenic dyslipidemia (AD), defined as decreased HDL-C plus raised triglycerides (TG). AD confers increased risk for CAD, even when LDL-C is at target. AD is rarely assessed due to lack of screening methods consensus. Aim: To establish the prevalence and...

  • Treat all type 2 diabetes patients as if they had a history of prior MI. Haffner, S.M.; Lehto, S. // Geriatrics;Oct98, Vol. 53 Issue 10, p91 

    Reports that according to the authors of a study in Finland, aggressive treatment should be administered to cardiovascular risk factors in patients with type 2 diabetes who have not had a myocardial infarction (MI). Amount of participants in the study; Age range of the participants; Comparison...

  • Ask Doctor Cory. SerVaas, Cory // Turtle;Jul/Aug2003, Vol. 25 Issue 4, p34 

    Addresses questions about diseases, such as heart attack and type 2 diabetes.

  • ERRATUM.  // Dysphrenia;2013, Vol. 4 Issue 2, p175 

    A correction to the article "A clinical study of the impact of stressful life events in the aetiology of non insulin dependent diabetes mellitus," which appeared in the June 2013 issue is presented.

  • LEAD-6 extension: Switch from exenatide to liraglutide further improved glycemic control. Kalvaitis, Katie // Endocrine Today;Nov2009, Vol. 7 Issue 13, p19 

    This article discusses a study which showed improvements in patients with type 2 diabetes who switched therapy from exenatide to liraglutide.

  • Repaglinide.  // Reactions Weekly;6/11/2011, Issue 1355, p30 

    The article describes the case of a 61-year-old man who developed a hypersensitivity to repaglinide while undergoing therapy for type 2 diabetes mellitus.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics